Company Profile
Nkarta Stock Price, News & Analysis
- Ticker:
- NKTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.29 USD (+4.09%)
Close
Last updated: August 6, 2026
208M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, NKTX closed up 4.09% at $2.29. No new same-company headline was identified in the current news window.
Company overview
Allogeneic CAR-NK Company
Nkarta develops off-the-shelf natural killer cell therapies for autoimmune disease and cancer.
NKX019
NKX019 is a CD19-directed CAR-NK therapy designed to deplete pathogenic B cells without patient-specific manufacturing.
Ntrust Studies
Ntrust-1 and Ntrust-2 evaluate NKX019 across autoimmune diseases with outpatient dosing and the option for redosing.
Future catalysts
Initial clinical data from Ntrust-1 and Ntrust-2 are planned for presentation at a medical meeting in 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Nkarta to Participate in March Investor Conferences
Source: Nkarta
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Nkarta (NKTX)?
Nkarta (NKTX) most recently closed at 2.29 USD, a +4.09% move versus the previous session.
What is the market cap of Nkarta (NKTX)?
Nkarta currently has a market capitalization of 208M USD on BioPharmSignal.
What does Nkarta do?
Allogeneic CAR-NK Company Nkarta develops off-the-shelf natural killer cell therapies for autoimmune disease and cancer. NKX019 NKX019 is a CD19-directed CAR-NK therapy designed to deplete pathogenic B cells without patient-specific manufacturing. Ntrust Studies Ntrust-1 and Ntrust-2 evaluate NKX019 across autoimmune diseases with outpatient dosing and the...
On which exchange is NKTX stock listed?
Nkarta (NKTX) is associated with NASDAQ, United States, Biopharma.
What is CAR-NK?
Allogeneic CAR-NK Company Nkarta develops off-the-shelf natural killer cell therapies for autoimmune disease and cancer.
Which conditions is Nkarta targeting with CAR-NK?
Nkarta is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Nkarta describe recent progress with CAR-NK?
Initial clinical data from Ntrust-1 and Ntrust-2 are planned for presentation at a medical meeting in 2026.
What is Allogeneic?
Allogeneic CAR-NK Company Nkarta develops off-the-shelf natural killer cell therapies for autoimmune disease and cancer.